TBX-2400 / Taiga Biotech - LARVOL DELTA

Taiga Initiates Phase 1/2 Clinical Study of TBX-2400 in Acute Myeloid Leukemia and Myelofibrosis in Croatia (PRNewswire) - "Taiga Biotechnologies...announced today that the Company has completed the site initiation session for the first site to participate in the TBX-2400-01 clinical trial, a Phase 1/2 study to evaluate the safety and early efficacy of TBX-2400 in acute myeloid leukemia (AML) and myelofibrosis patients undergoing hematopoietic stem cell transplant (HSCT), in Croatia."

Trial status • Acute Myelogenous Leukemia • Hematological Malignancies • Myelofibrosis • Oncology

Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis (clinicaltrials.gov) - P1; N=10; Not yet recruiting; Sponsor: Taiga Biotechnologies, Inc.; Initiation date: Jun 2021 ➔ Dec 2021

Clinical • Trial initiation date • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Myelofibrosis • Oncology • Transplantation • PTPRC

Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis (clinicaltrials.gov) - P1; N=10; Not yet recruiting; Sponsor: Taiga Biotechnologies, Inc.; Initiation date: Mar 2021 ➔ Jun 2021

Clinical • Trial initiation date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelofibrosis • Oncology • Transplantation • PTPRC

Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis (clinicaltrials.gov) - P1; N=10; Not yet recruiting; Sponsor: Taiga Biotechnologies, Inc.

Clinical • New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelofibrosis • Oncology • Transplantation